Collectively, the above data indicated that myeloid SHP2 loss sensitized Ly6Clow monocyte/macrophage polarization in thrombus tissues, thereby enhancing MMP2 and MMP9 activities to degrade intrathrombus collagen, which might be a promising therapeutic target in thromboembolic disease. The gene discussed is MMP9; the disease is Thromboembolism.